Please assess the completion status of the following clinical trial:

Trial Title: Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient at least 12 years of age~* Both genders; females of childbearing potential must be willing to use birth control method~* Pre-bronchodilator FEV1 of 40-90% predicted~* Reversibility FEV1 of at least 12% and 200mls~* Current asthma therapy that includes an inhaled corticosteroid for at least 12 weeks prior to first visit~Exclusion Criteria:~* History of life-threatening asthma~* Respiratory infection or oral candidiasis~* Asthma exacerbation within 12 weeks~* Concurrent respiratory disease or other disease that would confound study participation or affect subject safety~* Allergies to study drugs, study drugs' excipients, medications related to study drugs~* Taking another investigational medication or medication prohibited for use during this study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Furoate/Vilanterol (Type: EXPERIMENTAL): Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
- Fluticasone Furoate (Type: ACTIVE_COMPARATOR): Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
- Fluticasone Propionate (Type: ACTIVE_COMPARATOR): Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).